Integration Over Elimination

In this Point of View column, Mike Garrett, CEO of Taconic Biosciences, explores redefining preclinical models for the future of drug development. The question is no longer whether animal models still have a place in modern drug development, but how they can be used more judiciously and responsibly. When integration guides decision-making, the result is a more efficient therapeutic pipeline, greater regulatory confidence, and meaningful progress toward the goals of the 3Rs. A win for science; a win for patients; and, ultimately, a win for animals.

The post Integration Over Elimination appeared first on GEN - Genetic Engineering and Biotechnology News.